Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives

Table 4 Response and median survival after transarterial radioembolization in hepatocellular carcinoma with or without portal vein tumour thrombosis from recent studies (modified from Okuda et al[90])

Ref.	PVTT	n	Response (CR/PR) %WHO/RECIST criteria	RR (CR/PR) %EASL criteria	OS
Salem et al[71]	Child-Pugh A	116	52	69	17.2
TheraSphere1	No PVTT	81	53	77	22.1
no EHS	PVTT (mixed)	35	50	50	10.4
	First-order	19	58	58	16.6
	Main	16	40	40	7.7
	Child-Pugh B	122	39	52	7.7
	No PVTT	65	47	67	14.8
	PVTT (mixed)	57	28	32	5.6
	First-order	27	28	40	6.5
	Main	30	28	24	4.5
Hilgard et al[55]	All patients	108	15	40	16.4
TheraSphere1	No PVTT	75	NR	NR	16.4
30% EHS	PVTT [mixed: main (12); first/second order (12); unknown (9)]	33			10
Sangro et al[8]	All patients	325	NR	NR	12.8
SIR-Spheres2	No PVTT	249			15.3
9% EHS	PVTT [mixed: main (32); first order (44)]	76			10.7/9.7
Iñarrairaegui et al[94] TheraSphere1 and SIR-Spheres2	PVTT [mixed: main (6); first/second order (19)]	25	NR	NR	10
Tsai et al[95]	PVTT	22	NR	NR	7
TheraSphere1 and SIR-Spheres2	Main	12			4.4
13% EHS	First order	10			7
Woodall et al[96]	No PVTT	20	NR	NR	13.9
TheraSphere1	PVTT [mixed: main (10)]	15			3.2
Kulik et al[92]	All patients	108	42	70	NR
TheraSphere1	No PVTT	71			15.4
12% EHS	PVTT main	12			4.4
	First order	25			9.9

¹BTG International Canada Inc., Ottawa, Ontario, Canada;

²Sirtex Medical, North Sydney, Australia. PVTT: Portal vein tumor thrombosis; CR: Complete response; PR: Partial response; WHO: World Health Organization; RECIST: Response Evaluation Criteria in solid tumors; RR: Response rate; EASL: European Association for the Study of the liver; EHS: Extrahepatic disease; NR: Not reported; OS: Overall survival; Main: Main portal vein trunk; First order: Right and/or left portal vein; Second order: Segmental branches of portal vein.